Literature DB >> 24940318

Seroprevalence of HBV and HIV co-infection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South Nigeria.

E E Ikpeme1, O M Etukudo1, U E Ekrikpo2.   

Abstract

BACKGROUND: Human Immunodeficiency Virus/Hepatitis B Virus (HIV/HBV) co-infection in Nigerian children has emerged as a major concern with the advent of HAART. Its impact on the immune system and liver has not been extensively studied in children.
OBJECTIVES: To determine the prevalence of HBV seropositivity among HIV positive children on HAART and its effect on immune response and liver enzymes.
METHODS: All consecutive HIV positive children aged two months to seventeen years on HAART constituted the study population. Age and gender; CD4+ count, ALT, creatinine and HBsAg were tested and documented at enrolment and 12months.
RESULTS: One hundred and seventy one patients were seen over this period. Seventy-two (43.4%) were males while 94 (56.6%) were females giving a male: female ratio of 1:1.3. The mean age of the patients was 63±43.4 months. Prevalence of HIV/HBV co-infection was 6.02% (95% CI 2.4-9.7). There was no significant effect of HBV status on elevation of ALT levels with 12 months of HAART. Co-infected patients had an odds ratio of achieving immune response of 0.14 (95% CI 0.02-0.79).
CONCLUSION: HIV/HBV co-infection rates in our children are comparable to other localities. ALT levels do not worsen with HAART and immune response of the co-infected children on HAART is lower.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24940318      PMCID: PMC4056492          DOI: 10.4314/ahs.v13i4.14

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  23 in total

Review 1.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

Authors:  Alfredo Alberti; Nathan Clumeck; Simon Collins; Wolfram Gerlich; Jens Lundgren; Giorgio Palù; Peter Reiss; Rodolphe Thiebaut; Ola Weiland; Yazdan Yazdanpanah; Stefan Zeuzem
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

2.  Phylogenetic analysis of new hepatitis B virus isolates from Nigeria supports endemicity of genotype E in West Africa.

Authors:  S O Odemuyiwa; M N Mulders; O I Oyedele; S O Ola; G N Odaibo; D O Olaleye; C P Muller
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

3.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.

Authors:  Deborah Konopnicki; Amanda Mocroft; S de Wit; Francisco Antunes; Bruno Ledergerber; Christine Katlama; K Zilmer; Stefano Vella; Ole Kirk; Jens D Lundgren
Journal:  AIDS       Date:  2005-03-24       Impact factor: 4.177

4.  Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa.

Authors:  Denise Ilboudo; Jacques Simpore; Djeneba Ouermi; Cyrille Bisseye; Tani Sagna; Silvia Odolini; Fabio Buelli; Virginio Pietra; Salvatore Pignatelli; Charlemagne Gnoula; Jean-Baptiste Nikiema; Salvatore Musumeci
Journal:  Braz J Infect Dis       Date:  2010 May-Jun       Impact factor: 1.949

5.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

Review 6.  The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.

Authors:  G J Dore; D A Cooper
Journal:  Curr Opin Infect Dis       Date:  2001-12       Impact factor: 4.915

7.  HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Authors:  D Lincoln; K Petoumenos; G J Dore
Journal:  HIV Med       Date:  2003-07       Impact factor: 3.180

8.  Viral coinfections among African children infected with human immunodeficiency virus type 1.

Authors:  Rana Chakraborty; Gareth Rees; Dimitra Bourboulia; Alexandra M Cross; Jedediah R Dixon; Angelo D'Agostino; Rachel Musoke; Chris Boshoff; Sarah L Rowland-Jones; Paul Klenerman
Journal:  Clin Infect Dis       Date:  2003-03-19       Impact factor: 9.079

9.  Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.

Authors:  Mark S Sulkowski
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

10.  Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

Authors:  Carlo Torti; Giuseppe Lapadula; Salvatore Casari; Massimo Puoti; Mark Nelson; Eugenia Quiros-Roldan; Daniele Bella; Giuseppe Pastore; Nicoletta Ladisa; Lorenzo Minoli; Giovanni Sotgiu; Francesco Mazzotta; Sergio Lo Caputo; Giovanni Di Perri; Gaetano Filice; Carmine Tinelli; Giampiero Carosi
Journal:  BMC Infect Dis       Date:  2005-07-14       Impact factor: 3.090

View more
  9 in total

1.  The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Olatunji O Adetokunboh; Ajibola Awotiwon; Duduzile Ndwandwe; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

2.  Infections and non-communicable diseases that just refuse to go away.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2013-12       Impact factor: 0.927

3.  Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria.

Authors:  Sandra Olukemi Ogwu-Richard; David Ajiboye Ojo; Olusola Abiodun Akingbade; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

4.  Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment Outcomes.

Authors:  Kathryn Peebles; Lweendo Nchimba; Roma Chilengi; Carolyn Bolton Moore; Mwangelwa Mubiana-Mbewe; Michael J Vinikoor
Journal:  J Trop Pediatr       Date:  2015-09-02       Impact factor: 1.165

5.  Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia.

Authors:  Bayeh Abera; Yohanes Zenebe; Wondemagegn Mulu; Mulugeta Kibret; Getachew Kahsu
Journal:  BMC Res Notes       Date:  2014-11-25

6.  Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.

Authors:  Mary Adetola Lawal; Oluwafunmilayo Funke Adeniyi; Patricia Eyanya Akintan; Abideen Olurotimi Salako; Olorunfemi Sunday Omotosho; Edamisan Olusoji Temiye
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

7.  Seroprevalence of HBV among people living with HIV in Anyigba, Kogi State, Nigeria.

Authors:  Cornelius Arome Omatola; Joshua Idofe; Martin-Luther Oseni Okolo; Patience Omebije Adejo; Mesach Maunta Maina; Joseph Abraham Oyiguh
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

8.  Detection of Hepatitis B Surface Antigen among Febrile Patients in Ankpa, Kogi State, Nigeria.

Authors:  Cornelius Arome Omatola; Bernard Anyebe Onoja; Joseph Agama
Journal:  J Trop Med       Date:  2020-02-11

9.  Impact of Highly Active Antiretroviral Therapy on Chronic Hepatitis B Serological Markers among Senegalese HIV Co-infected Children.

Authors:  Abou Ba; Fatou K Ndiaye; Yaay J Djeng; Cecile Cames; Aminata Diack; Ousmane N'diaye
Journal:  Int J MCH AIDS       Date:  2019-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.